Abstract CT219: Phase I trial of in situ vaccination with autologous CCL21 gene-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced non-small cell lung cancer (NSCLC)

Bin Liu(Jilin University), Steven M. Dubinett(University of California, Los Angeles), Robert D. Suh(University of California, Los Angeles), Anita Kaul(University of California, Los Angeles), Kanwarpal Kahlon(City Of Hope National Medical Center), Shahryar Ashouri(APLA Health), Gregory A. Fishbein(University of California, Los Angeles), Raymond J. Lim(University of California, Los Angeles), Jonathan W. Goldman(University of California, Los Angeles), Michael S. Oh(Northwestern University), Zhe Jing(University of California, Los Angeles), Fereidoun Abtin, Scott Oh, Linh M. Tran(University of California, Los Angeles), Scott Genshaft(University of California, Los Angeles), Edward B. Garon(University of California, Los Angeles), Ciara M. O'Higgins(APLA Health), Kostyantyn Krysan(University of California, Los Angeles), David Elashoff(University of California, Los Angeles), Aaron Lisberg(University of California, Los Angeles), Jay Lee(APLA Health), Ramin Salehi‐Rad(University of California, Los Angeles), Camelia Dumitras(University of California, Los Angeles)

Cancer Research

June 15, 2022

Cited by 1

|New England Journal of Medicine|2020|1.7k

|New England Journal of Medicine|2020|766

|New England Journal of Medicine|2015|664

|New England Journal of Medicine|2023|605

|Journal of the National Comprehensive Cancer Network|2021|459

Abstract CT219: Phase I trial of <i>in situ</i> vaccination with autologous <i>CCL21</i> gene-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced non-small cell lung cancer (NSCLC)